[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromyelitis-optica-spectrum-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromyelitis-optica-spectrum-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,71,98,123,145,175,203,230,255,276,304],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100547875","phase-2-a-clinical-study-of-b001-injection-in-the-treatment-of-neuromyelitis-optica-spectrum-disordersnmosd-100547875",false,"NCT06413654","A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Clinical Study to Evaluate the Efficacy and Safety of B001 Injection in Aquaporin-4 Antibody Positive Patients With Neuromyelitis Optica Spectrum Disorder","Inclusion Criteria:\n\n1. Confirmed NMOSD patients;\n2. Experienced at least 1 recurrence of NMOSD within 1 year or at least 2 recurrence within 2 years prior to screening;\n3. The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation;\n4. Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent; Willing to follow and able to complete all test procedures.\n\nExclusion Criteria:\n\n1. Subjects with severe NMOSD were judged by the researcher to be unfit to participate in this study;\n2. Subjects with chronic active immune system diseases undergoing systematic treatment;\n3. Received anti-CD20 or other cell depletion therapy within 6 months before first dose;\n4. Received the prescribed drug treatment at the prescribed time before first dose;\n5. Subjects who have participated in any drug clinical trials within 28 days prior to the first dose;\n6. Received hematopoietic stem cell transplantation、 lymphatic irradiation before first dose;\n7. Pregnant or lactating women; Subjects with birth plans during the trial;\n8. Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial;\n9. Subjects with severe, progressive, or uncontrolled disease who have been assessed by the investigator to be at increased risk of participating in the study;\n10. A history of gastrointestinal perforation and\u002For fistula within 6 months prior to screening;\n11. Subjects who received a live or attenuated vaccine within 4 weeks prior to initial administration, or who plan to receive vaccination during the study period;\n12. Subjects with severe or persistent infection currently or within the 1 months prior to screening;\n13. Subjects with positive gamma interferon release test;\n14. Subjects who currently have active hepatitis or have a history of severe liver disease;\n15. Uncontrolled systemic disease, or any other reason the investigator deems inappropriate for inclusion;\n16. Abnormal laboratory test results;\n17. Subjects with a history of alcohol or drug abuse in the 6 months prior to screeing, or who are abusing;\n18. Subjects with symptoms of severe mental illness who are clinically uncooperative;\n19. Subjects who were unable to undergo magnetic resonance imaging during the study and who had other conditions that the investigator considered inappropriate to enroll.","ALL","18 Years",{"count":19,"type":20},132,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.",[27],"Neuromyelitis Optica Spectrum Disorders","RECRUITING","2026-04-29",{"date":31,"type":32},"2026-05-05","ACTUAL",{"date":34,"type":32},"2024-07-17",{"date":36,"type":20},"2029-02-28",{"name":38,"class":39},"Shanghai Jiaolian Drug Research and Development Co., Ltd","INDUSTRY",51,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100633408","anticipating-irreversible-disability-in-neuromyelitis-optica-spectrum-disorder-a-study-to-assess-disease-activity-in-apparently-stable-patients-100633408","NCT07526298","Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Apparently Stable Patients","Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Multicenter Prospective Observational Study to Assess Disease Activity in Apparently Stable Patients","Inclusion Criteria:\n\n* Adult patients (age ≥18 years);\n* NMOSD diagnosis with AQP4 IgG positive status assessed with a cell-based assay;\n* Under rituximab treatment (standard of care) from at least 1 year and for not more than 5 years;\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* History of a clinical relapse or new\u002Fenlarging T2 lesion during the 6 months preceding the enrollment;\n* Steroids treatment during 30 days before the enrollment;\n* Any contraindication to MRI;\n* Patients currently participating in a different clinical trial;\n* Patients currently pregnant.",{"count":49,"type":20},50,"12 Months","OBSERVATIONAL","The present research is an observational clinical study. The project aims to investigate astrocytic damage, assessed through biological findings such as an increase in GFAP level and\u002For MRI water index, in patients with NMOSD and its potential role in predicting demyelinating relapses or affecting disability outcomes. It will also explore predictors of astrocytic relapses, focusing on demographic, clinical, and immunological biomarkers like T cell responses, B cell repopulation, and cytokine levels. The goal is to identify unrecognized disease activity, providing insights for future research and clinical trials.\n\nThe study will involve 8 sites in Italy: 6 NMOSD clinical centers for patient enrolment and 2 centers for bioengineering and biological analysis. Centralized analysis of the MRI images of all patients enrolled in the clinical centers will be performed by the Neuroimaging Research Unit Fase 1 of San Raffaele Hospital. A total of 50 patients will be included and they will be followed for 12 months.\n\nComprehensive evaluation of patients, including clinical assessment, bioengineering evaluation, MRI, and blood samples, will be conducted at baseline, month 6, and month 12. To assess silent astrocytic relapses, a specialized evaluation will take place at months 3 and 9, including clinical analysis, blood samples to assess biomarkers like GFAP, a reduced MRI protocol to assess MRI water index, and bioengineering evaluation. In the case of a classical relapse, a dedicated visit will occur within 5 days of symptom onset, using the same evaluation protocol as at months 3 and 9 (MRI and biomarkers will be evaluated if not done in the month before).",[27],[55,56,57,58],"Relapse","Astrocytic damage","MRI","GFAP","NOT_YET_RECRUITING","2026-04-10",{"date":62,"type":32},"2026-04-13",{"date":64,"type":20},"2026-04-01",{"date":66,"type":20},"2027-04-01",{"name":68,"class":69},"IRCCS San Raffaele","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":70},"100623122","early-phase-1-universal-chimeric-antigen-receptor-t-cell-ucar-t-cell-therapy-targeting-cd19-bcmaqt-019c-in-patients-with-r-r-neurological-autoimmune-diseases-100623122","NCT07392528","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002F BCMA（QT-019C） in Patients With r\u002F r Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA（QT-019C） in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years. The following conditions are excluded: non-melanoma skin cancer, stage I tumors that have a low recurrence probability after complete resection, clinically localized prostate cancer after treatment, cervical carcinoma in situ confirmed by biopsy or squamous intraepithelial lesion shown on smear, stable papillary thyroid carcinoma or follicular thyroid carcinoma.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.",{"count":79,"type":20},15,[81],"EARLY_PHASE1","This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells（QT-019C）.",[27,84,85],"Multiple Sclerosis","Myasthenia Gravis",[87,88],"Universal Allogeneic CAR T-cells","QT-019C","2026-02-08",{"date":91,"type":32},"2026-02-11",{"date":93,"type":20},"2026-03",{"date":95,"type":20},"2028-12",{"name":97,"class":69},"Tianjin Huanhu Hospital",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":70},"100563795","phase-1-the-safety-and-efficacy-of-nouvsoma001-in-neuromyelitis-optica-spectrum-disorders-100563795","NCT06620809","The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders","An Open-Label Exploratory Clinical Trial to Assess the Safety and Efficacy of NouvSoma001 in the Treatment of Neuromyelitis Optica Spectrum Disorders","Inclusion Criteria:\n\n1. Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies.\n2. Symptom onset occurred within 7 days prior to enrollment, with associated severe pain, lower limb motor dysfunction, or urinary\u002Fbowel impairment.\n3. Males or Females aged between 18 and 65 years.\n4. The Expanded Disability Status Scale (EDSS) score prior to the current disease episode is ≤ 4.\n5. Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.\n6. Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.\n\nExclusion Criteria:\n\n1. Abnormal laboratory indicators of the subjects need to be excluded, including, but not limited to, the following indicators:\n\n   White Blood Cell Count \\<3\\*10\\^9\u002FL Neutrophil Count \\<1.5\\*10\\^9\u002FL \\<1.5\\*10\\^9\u002FL Hemoglobin \\<85 \\<85 g\u002FL Platelet Count \\<80\\*10\\^9\u002FL \\<80\\*10\\^9\u002FL Serum Creatinine \\>1.5\\*ULN Total Bilirubin \\>1.5\\*ULN AST (GOT) \\>3\\*ULN ALT (GPT) \\>3\\*ULN Alkaline Phosphatase \\>2\\*ULN (AST = Aspartate Aminotransferase; GOT = Glutamic-Oxaloacetic Transaminase; ALT = Alanine Aminotransferase; GPT = Glutamic-Pyruvic Transaminase)\n2. Any contraindications to lumbar puncture.\n3. Pregnant or breastfeeding women, and patients with plans to conceive during the trial.\n4. Patients with a known history of allergies to human-derived biological products or those with an allergic predisposition.\n5. Patients who have undergone hematopoietic stem cell transplantation or lymphatic irradiation before enrollment.\n6. Patients who have participated in any other clinical trial within the last 3 months.\n7. Patients with severe comorbidities, including immunodeficiency or coagulation disorders.\n8. Patients with active suicidal ideation within 6 months before screening or have a history of suicide attempts within 3 years before screening.\n9. Patients with severe psychiatric symptoms that prevent clinical cooperation.\n10. Patients with positive for alcohol addiction or drug abuse.\n11. Patients with malignant tumors.\n12. Patients who have experienced any of the following events within 12 weeks before enrollment: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Class IV heart failure.\n13. Patients with persistent systemic infections and severe local infections.\n14. Patients unable to undergo magnetic resonance imaging during the trial.\n15. Patients deemed unsuitable for participation by the investigator.","65 Years",{"count":107,"type":20},69,[109],"PHASE1","This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.",[27],[27,113],"extracelluar vesicles","2026-01-18",{"date":116,"type":32},"2026-01-21",{"date":118,"type":32},"2025-03-28",{"date":120,"type":20},"2027-11-30",{"name":122,"class":69},"Tongji Hospital",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":70},"100588266","early-phase-1-universal-chimeric-antigen-receptor-t-cell-ucar-t-cell-therapy-targeting-cd19b-cell-maturation-antigen-cd19bcma-in-patients-with-rr-neurological-autoimmune-diseases-100588266","NCT06939166","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002FB Cell Maturation Antigen （CD19\u002FBCMA） in Patients With r\u002Fr Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.",{"count":5,"type":20},[81],"This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells.",[27,85,84,134,135],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Autoimmune Encephalitis",[87],"2025-12-11",{"date":139,"type":32},"2025-12-15",{"date":141,"type":32},"2025-06-17",{"date":143,"type":20},"2027-10",{"name":97,"class":69},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":70},"100608510","integrating-metabolism-connectivity-and-mesoscale-imaging-at-ultra-high-field-to-decipher-mechanisms-of-resilience-and-neurodegeneration-in-neurological-diseases-and-healthy-aging-100608510","NCT07202494","Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging","MESO7","Inclusion Criteria:\n\n* Age:Female or male, aged 18 years or older.\n* Health Status: No uncontrolled general diseases, such as cancer, autoimmune diseases, liver failure, severe or untreated high blood pressure, or severe rhythm disorders. No chronic psychiatric illnesses, including severe dementia.\n* MRI Compatibility: No contraindications for MRI exams (e.g., claustrophobia, metal foreign bodies, pacemakers, severe kidney failure).\n* Social Security Coverage: Participants must have social security coverage.\n* Informed Consent: The participant must have read, understood, and signed the informed consent after being adequately informed about the study.\n* Specific Disease Criteria (For Disease Groups): Specific inclusion criteria apply to each pathology, such as MS (based on McDonald criteria), NMOSD (Wingerchuk 2015), Alzheimer's (meeting NINCDS-ADRDA criteria), etc.\n\nExclusion Criteria:\n\n* Pregnancy: Pregnant women are excluded from the study.\n* Inability to Provide Informed Consent:\n* Any participant who refuses to sign the informed consent or is unable to do so due to mental or physical conditions.\n* Refusal of MRI: Individuals who refuse to undergo brain MRI.\n* Contraindications for MRI:Participants with contraindications for MRI exams, such as claustrophobia, metal foreign bodies, pacemakers, or severe kidney failure.\n* Medical Conditions: Known allergy to Dotarem (contrast agent) for neuroinflammatory patients. Individuals with severe renal insufficiency or other conditions that prevent MRI scanning.\n\nCognitive or Psychiatric Issues:\n\nChronic psychiatric conditions, including severe dementia or cognitive dysfunction that could hinder participation.\n\nLegal or Institutional Restrictions:\n\nAdults under legal protection (e.g., under guardianship or curatorship). Individuals deprived of their liberty.\n\nOther Medical Conditions:\n\nIndividuals with neurological diseases such as ischemic accidents, brain trauma, or encephalitis.\n\nPatients on treatments that would interfere with the study, as outlined for each disease.\n\nAllergy to Contrast Agent:\n\nAllergy to Dotarem for neuroinflammatory patients (MS, NMOSD, etc.).\n\nInability to Adhere to Protocol:\n\nParticipants who are unable or unwilling to comply with the study protocol.",true,"90 Years",{"count":155,"type":20},700,"The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological diseases and healthy aging. It leverages advanced multiparametric brain and spinal cord imaging at high (3T) and ultra-high magnetic fields (7T) to assess structural, functional, metabolic, and mesoscale changes in the central nervous system (CNS). Particular emphasis is placed on sodium (23Na-MRI) and phosphorus (31P-MRI) imaging, along with layer-dependent brain connectivity analysis.\n\nThe primary objective is to evaluate the impact of neuronal energy failure, measured via sodium concentration, on functional and structural reorganization in both healthy individuals and patients with various neurological conditions. Directed brain network models will be constructed from MRI data to quantify the connectivity strength (in- and out-degree) of cortical nodes. These connectivity metrics will be correlated with sodium concentrations to assess energy failure and its role in network reorganization. Longitudinal follow-up over two years is planned for subgroups with clinically progressive diseases.\n\nSecondary objectives include decoding metabolic, microstructural, and functional signatures of successful aging at the laminar level; characterizing disease-specific patterns of cortical and spinal microstructure associated with physical and cognitive dysfunction; describing longitudinal mesoscale and metabolic changes; and generating representative normative imaging datasets for the neuroscience community.\n\nThe study plans to enroll a total of 540 patients across 9 neurological conditions:Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), MOG Antibody Disease (MOGAD), Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), temporal and non-temporal epilepsy, and mild traumatic brain injury (mTBI),in addition to 160 age- and sex-matched healthy controls, totaling 700 participants. Imaging and clinical assessments will be performed at the CEMEREM center at Timone University Hospital, AP-HM, Marseille, France.\n\nEach participant will undergo multiparametric brain and spinal cord MRI, including DTI, BOLD, MP2RAGE, SWI, quantitative sodium and phosphorus imaging, and functional assessments including neuropsychological testing, visual and motor function tests. Disease-specific assessments such as OCT, evoked potentials, and disability scores (e.g., EDSS for MS) will also be included when appropriate.\n\nThe study is expected to improve understanding of CNS adaptation mechanisms and support the development of more accurate diagnostic and prognostic tools for neurodegenerative diseases",[84,27,158,159,160,161,162,163,164,165],"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)","Alzheimer Disease","Parkinson Disease","Amyotrophic Lateral Sclerosis (ALS)","Temporal Lobe Epilepsy","Epilepsy","Mild Traumatic Brain Injury","Healthy Aging","2025-09-29",{"date":168,"type":32},"2025-10-01",{"date":170,"type":32},"2025-05-19",{"date":172,"type":20},"2030-05-18",{"name":174,"class":69},"Assistance Publique Hopitaux De Marseille",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":70},"100574789","protein-a-immunoadsorption-for-the-treatment-of-acute-episodes-of-neuromyelitis-optica-spectrum-disorder-100574789","NCT06763848","Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder","Protein A Immunoadsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder：A Multicenter, Open-label, Superiority, Randomised Trial","PANDA","Inclusion Criteria:\n\n* The inclusion criteria for the study are as follows:\n\n  1. clinical diagnosis of acute Neuromyelitis Optica Spectrum Disorders (NMOSD)\n  2. Age and Gender: Participants must be between 18 and 65 years old, inclusive, with no gender restrictions.\n  3. Serological Marker: Participants must test positive for AQP4-IgG using the cell-based assay (CBA) method.\n  4. Understanding and Consent: Participants or their legal representatives must be able to understand the study's purpose, demonstrate sufficient compliance with the study protocol, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding.\n2. Participants who cannot establish peripheral or central venous access, or have a history of allergic reactions to plasmapheresis.\n3. Participants with contraindications to intravenous methylprednisolone treatment.\n4. Participants who have used monoclonal antibodies in the last 6 months, or FcRn antagonists in the last 3 months.\n5. Participants who must use ACE inhibitors (ACEI) within 1 week before the start of treatment or during the study, and cannot discontinue their use.\n6. Severe Bleeding or Bleeding Disorders\n7. Severe Heart Failure\n8. Severe Infections",{"count":184,"type":20},144,[186],"NA","To clarify the efficacy and safety of protein A immunoadsorption therapy for acute exacerbations of neuromyelitis optica spectrum disorders(NMOSD), we designed a multicenter, open-label, superiority randomized controlled clinical trial, planning to enroll 144 patients with NMOSD. We plan to treat patients with acute NMOSD using protein A immunoadsorption combined with high-dose intravenous methylprednisolone, and compare this with treatment using high-dose intravenous methylprednisolone alone. The aim is to observe the impact and safety of protein A immunoadsorption on the treatment efficacy for these patients experiencing acute exacerbations of NMOSD, ultimately providing more comprehensive clinical evidence to support treatment protocols for the acute phase of NMOSD.",[27],[190,191,192,193],"neuromyelitis optica spectrum disorders","immunoadsorption","acute episodes","treatment","2025-04-27",{"date":196,"type":32},"2025-04-30",{"date":198,"type":32},"2025-04-25",{"date":200,"type":20},"2026-12-31",{"name":202,"class":69},"Third Affiliated Hospital, Sun Yat-Sen University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":70},"100582589","frequency-of-fcgr3a-gene-polymorphisms-in-patients-with-neuromyelitis-optica-spectrum-disorders-anti-oligodendrocyte-myelin-protein-antibody-disease-and-multiple-sclerosis-100582589","NCT06865274","Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.","Multicenter Prospective Interventional Study to Evaluate the Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody Disease, and Multiple Sclerosis.","PoGe","Inclusion Criteria:\n\n* Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers\n* Patients aged ≥ 18 years\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Individuals under 18 years of age\n* Inability to provide informed consent",{"count":49,"type":20},[186],"The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in a a comparison group of patients affected with Multiple Sclerosis (MS).\n\nThe study will involve adult patients diagnosed with MS, NMOSD, or MOGAD, followed at various clinical centers in the Lazio region.\n\nPatients from the participating clinical centers will be selected, and their medical records will be analyzed to collect clinical and neuroimaging data. The data will include demographic information such as age, sex and body mass index and clinical information such as age at disease onset, disease duration, antibody status (AQP4+\u002F- and MOG+\u002F-), disease-modifying therapies, as well as MRI data and the Expanded Disability Status Scale (EDSS) score.\n\nEach patient included in the study will undergo a single blood draw of approximately 5 ml of peripheral venous blood during routine blood tests, which will be used for DNA extraction and polimorphysm analysis. Demographic and clinical differences between patients with NMOSD and MOGAD, with and without the polymorphism, will be assessed and compared with the group of patients with MS.",[27,215,84],"MOGAD",[217,215,218,219,220],"NMOSD","MS","polymorphysm","FCG3A","2025-03-05",{"date":223,"type":32},"2025-03-07",{"date":225,"type":32},"2025-02-20",{"date":227,"type":20},"2027-02-28",{"name":229,"class":69},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":70},"100553372","early-phase-1-universal-car-t-cells-in-patients-with-refractory-autoimmune-diseases-of-the-nervous-system-100553372","NCT06485232","Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.","An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System","Inclusion Criteria:\n\n* Aged 18-75 years (for MS patients, 18-55 years); both genders eligible.\n* Subjects with refractory neurological autoimmune diseases who have failed standard treatment or lack effective treatment, Including neuromyelitis optica spectrum disorders(NMOSD), generalized myasthenia gravis(gMG), chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP) and multiple sclerosis(MS).\n* Anticipated survival of ≥ 12 weeks as judged by the researcher.\n* Agrees to use double barrier methods, condoms, oral or injectable contraceptives, or intrauterine devices during the study period and for one year after taking the study medication.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* History of solid organ transplantation.\n* Malignant tumor within the last two years.\n* Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb), with peripheral blood Hepatitis B virus (HBV) DNA detected as positive; positive for Hepatitis C virus antibodies, with peripheral blood Hepatitis C virus RNA detected as positive; positive for Human Immunodeficiency Virus (HIV) antibodies; positive for Cytomegalovirus (CMV) DNA; positive for syphilis.\n* Primary immunodeficiency (congenital or acquired).\n* Severe cardiac disease.\n* History of psychiatric disorders or history of psychotropic drug abuse, with no history of withdrawal.\n* Allergic constitution or a history of severe allergies.\n* Pregnant or breastfeeding women.","75 Years",{"count":239,"type":20},25,[81],"This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system. This study aims to evaluate the safety and efficacy of the treatment with universal BCMA and CD19 CART.",[27,243,84,134],"Myasthenia Gravis, Generalized",[245,27,85,84,134],"universal CAR-T","2024-12-30",{"date":248,"type":32},"2025-01-01",{"date":250,"type":20},"2025-02-28",{"date":252,"type":20},"2027-12-31",{"name":254,"class":69},"Xuanwu Hospital, Beijing",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":70},"100569691","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-jyp0061-in-patients-with-acute-neuromyelitis-spectrum-disease-nmosd-100569691","NCT06697535","A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)","Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD): a Multicenter, Randomized, Open-label, Positive-controlled, Two-stage Exploratory Phase 2 Trial","Inclusion Criteria:\n\n* Neuromyelitis spectrum disease (NMOSD) patients according to 2015 International consensus diagnostic criteria.\n* Positive Aquaporin 4 immunoglobulin G (AQP4-IgG)\n* Patients with acute NMOSD\n* Female serum pregnancy test results were negative at the time of screening, subject (including partner) had no child-rearing plan and voluntarily adopted double contraceptive (non-oral contraceptives) within 6 months from screening to the last study drug administration, and had no sperm\u002Fegg donation plan;\n* Have fully understood this study, voluntarily participate in the experiment, and voluntarily sign the written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Suspected or clear allergy to similar ingredients or any ingredient in the study drug, or allergic constitution;\n* Symptoms improved in the acute phase before the study drug was used;\n* Unable to complete MRI or gadolinium enhanced examination;",{"count":263,"type":20},35,[23],"The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients. Participants will be treated with low-dose JYP0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose JYP0061. Efficacy and safety evaluations will be conducted according to the protocol.",[27],"2024-11-19",{"date":269,"type":32},"2024-11-20",{"date":271,"type":32},"2023-05-24",{"date":273,"type":20},"2026-07-30",{"name":275,"class":39},"Guangzhou JOYO Pharma Co., Ltd",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":283,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":285,"conditions":286,"keywords":292,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":70},"100557708","sun-yat-sen-cohort-of-cns-idiopathic-inflammatory-demyelinating-diseases-100557708","NCT06541626","Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases","Sun Yat-Sen Prospective Cohort Study of Central Nervous System Idiopathic Inflammatory Demyelinating Diseases","Inclusion Criteria:\n\n1. Patients aged 18-65 years with central nervous system idiopathic inflammatory demyelinating diseases (CNS IIDD);\n2. The clinical syndrome of the attack meets one of the following: MS, NMOSD, MOGAD, ADEM, clinically isolated syndrome, demyelinating encephalopathy, demyelinating myelitis, or brainstem encephalitis (see below A-E);\n3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. History of tumors or diagnosis of central nervous system tumors;\n2. Infectious lesions of the central nervous system;\n3. Hereditary, metabolic, toxic, vascular, or traumatic demyelinating diseases of the brain\u002Fspinal cord;\n4. Non-compliance with treatment and follow-up.",{"count":284,"type":20},450,"The goal of this observational study is to learn about pathogenesis and clinical prognosis of CNS IIDD in the Chinese population and to provide evidence-based clues for clinical treatment decisions.\n\nThe main questions it aims to answer are:\n\nQuestion 1: Clarify the clinical characteristics and prognostic factors of various diseases (MS, NMOSD, MOGAD, etc.) within IIDD in the Chinese population.\n\nQuestion 2: Analyze the relationship between biomarkers and the occurrence, progression, and prognosis of CNS IIDD cases in our hospital.\n\nParticipants will\n\n1. Receive the recommended diagnosis and treatment plans from current international and national guidelines or expert consensus, without additional special interventions.\n2. Receive clinical evaluation, follow-up, and management from dedicated neuroimmunology specialists.",[287,27,288,289,290,291],"Multiple Sclerosis, MS","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Acute Disseminated Encephalomyelitis","Clinically Isolated Syndrome","Demyelinating Disorder",[293,294],"CNS IIDD","follow-up","2024-08-02",{"date":297,"type":32},"2024-08-07",{"date":299,"type":32},"2024-01-01",{"date":301,"type":20},"2035-12-31",{"name":303,"class":69},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":152,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":314,"conditions":315,"keywords":322,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":70},"100454970","ms-researchbiomarkers-100454970","NCT05204459","MS-ResearchBiomarkerS","Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders","MS-ReBS","Inclusion Criteria:\n\n* Subjects who meet any one of the following diagnostic criteria:\n\n  * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.\n  * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.\n  * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.\n  * Diagnosis of neurological disorders other than MSRD.\n  * Healthy volunteer.\n* Age ≥18.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).\n* Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.\n* Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT\u002FOCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).",{"count":313,"type":20},1000,"This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and\u002For spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.",[84,316,317,318,290,319,27,288,320,321,165],"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive","Radiologically Isolated Syndrome","Neurologic Autoimmune Disease","Neurologic Disorder",[84,316,317,318,290,319,27,323,320,321,165],"Myelin oligodendrocyte glycoprotein antibody-associated disease","2024-02-05",{"date":326,"type":32},"2024-02-06",{"date":328,"type":32},"2021-11-11",{"date":330,"type":20},"2041-11-11",{"name":332,"class":69},"Cedars-Sinai Medical Center"]